Literature DB >> 9697722

Increased immune activation precedes the inflection point of CD4 T cells and the increased serum virus load in human immunodeficiency virus infection.

J F Salazar-Gonzalez1, O Martinez-Maza, P Nishanian, N Aziz, L P Shen, S Grosser, J Taylor, R Detels, J L Fahey.   

Abstract

The temporal relationship of serum levels of human immunodeficiency virus (HIV) RNA and of immune activation products in 10 HIV-seropositive persons who showed an accelerated decline (inflection point) in CD4 T cell counts and went on to develop AIDS and in 10 matched controls without inflection point were examined. Cases and controls did not differ statistically at the baseline time point for this study. CD4 cell inflection points occurred 18-30 months before AIDS development. Serum levels of soluble tumor necrosis factor receptor II, soluble interleukin-2 receptor, beta2-microglobulin, and neopterin increased significantly > or = 6 months before the CD4 cell inflection point. In contrast, increases in mean HIV RNA levels occurred at the time of the CD4 cell inflection point. These data are consistent with the view that in vivo immune activation precedes the increases in virus load and is followed by an accelerated and rapid loss of CD4 lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9697722     DOI: 10.1086/515629

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Highly active antiretroviral therapy (HAART) and circulating markers of immune activation: specific effect of HAART on neopterin.

Authors:  N Amirayan-Chevillard; H Tissot-Dupont; Y Obadia; H Gallais; J L Mege; C Capo
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

Review 2.  Serological markers of disease activity in tuberculosis and HIV infection.

Authors:  A Marchant
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

3.  Incorporation of HLA-DR into the envelope of human immunodeficiency virus type 1 in vivo: correlation with stage of disease and presence of opportunistic infection.

Authors:  S D Lawn; S T Butera
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  Mucosal immunity in human and simian immunodeficiency lentivirus infections.

Authors:  J M Brenchley
Journal:  Mucosal Immunol       Date:  2013-04-03       Impact factor: 7.313

5.  Decreased CD40 ligand induction in CD4 T cells and dysregulated IL-12 production during HIV infection.

Authors:  G Vanham; L Penne; J Devalck; L Kestens; R Colebunders; E Bosmans; K Thielemans; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 6.  Microbial translocation, immune activation, and HIV disease.

Authors:  Nichole R Klatt; Nicholas T Funderburg; Jason M Brenchley
Journal:  Trends Microbiol       Date:  2012-10-11       Impact factor: 17.079

7.  Interleukin-12 is necessary for the priming of CD4+ T cells required during the elicitation of HIV-1 gp120-specific cytotoxic T-lymphocyte function.

Authors:  Shalini Gupta; Ramanamurthy Boppana; Gyan C Mishra; Bhaskar Saha; Debashis Mitra
Journal:  Immunology       Date:  2008-02-20       Impact factor: 7.397

Review 8.  Dendritic cell dysregulation during HIV-1 infection.

Authors:  Elizabeth Miller; Nina Bhardwaj
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 9.  Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm.

Authors:  Emily S Ford; Camille E Puronen; Irini Sereti
Journal:  Curr Opin HIV AIDS       Date:  2009-05       Impact factor: 4.283

10.  Levels of cytokines and immune activation markers in plasma in human immunodeficiency virus infection: quality control procedures.

Authors:  N Aziz; P Nishanian; J L Fahey
Journal:  Clin Diagn Lab Immunol       Date:  1998-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.